At a glance
ClinicalIndex Comparison Record- ✓Smoked at least 10 cigarettes per day for 3 or more months
- ✓Weighs at least 90 lbs
- ✓Motivated to quit smoking and has had at least one previous failed quit attempt
- ✓Speaks, reads, and writes English
- ✕History of bipolar disorder, eating disorder, schizophrenia, schizoaffective disorder, autism, or non-nicotine substance use disorder in the 6 months prior to study entry
- ✕Currently suicidal or history of suicide attempt in the 6 months prior to study entry
- ✕Psychotic symptoms
- ✕Use of psychotropic medications
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stress Response and Smoking Cessation in Depressed Youth
In Brief
A Phase 2 clinical trial evaluating Bupropion-SR and Placebo for Tobacco Use Cessation and Tobacco Use Disorder. Completed, enrolled 172 participants across 1 site.
Detailed Summary
Little is known about the best ways to help young people stop smoking. Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers. The purpose of this study is to determine if bupropion is also effective in treating smokers between the ages of 12 and 25 years old. This study also compares the effectiveness of bupropion used as a supplement to behavioral treatment versus behavioral treatment used alone. In addition, the study evaluates whether hormonal response to stress measured prior to the start of treatment predicts whether individuals respond well to treatment with medication.
Study Details
Timeline
Interventions
150mg tablets taken orally twice daily for 9 weeks.
Matching placebo (to Buproion-SR) twice daily for 9 weeks.